OncLive TV

A. David McCollum, MD, Baylor-Sammons Cancer Center, discusses integrating immunotherapy into the treatment landscape of colorectal cancer (CRC).

Sameh Mikhail, MD, medical oncologist, The Mark H. Zangmeister Cancer Center, discussing ongoing trials for patients with multiple myeloma.

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the ARCHES study for patients with prostate cancer.

Leo I. Gordon, MD, a professor of medicine at Feinberg School of Medicine, Northwestern University, discusses clinical trials in Hodgkin lymphoma.

Michael R. Harrison, MD, assistant professor of medicine, Duke Cancer Institute, discusses choosing frontline treatment for patients with renal cell carcinoma (RCC).

Terence Friedlander, MD, an assistant clinical professor in the Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses checkpoint inhibitors in the second-line setting for patients with bladder cancer.

Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses novel approaches for IP therapy for patients with ovarian cancer.

Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses novel combinations for the treatment of patients with melanoma.

Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the clinical trial landscape for melanoma

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the BOLERO-2 results for patients with hormone receptor (HR)-positive breast cancer.

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the importance of biomarker testing in lung cancer.

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the treatment of patients with colorectal cancer (CRC) that are microsatellite stable.

Lajos Pusztai, MD, professor of medicine, chief of Breast Medical Oncology, Yale Cancer Center and Yale School of Medicine, discusses the challenges facing neoadjuvant treatment of patients with HER2-positive breast cancer

Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, discusses the challenges of using anticoagulants in children with cancer.

Ingfrid Haldorsen, MD, University of Bergen, Haukeland University Hospital, discusses the challenges with imaging in endometrial cancer.

Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses a 92-gene assay of patients with neuroendocrine tumors (NETs).

Justin F. Gainor, MD, assistant professor of medicine, Harvard Medical School, attending physician, Massachusetts General Hospital, discusses the future of treatment for patients with EGFR-positive non-small cell lung cancer.

Peter R. Dottino, MD, professor of obstetrics, gynecology and reproductive science, Mount Sinai Hospital, discusses targeted therapies for patients with ovarian cancer.

Owen O'Connor, MD, PhD, professor of medicine and Experimental Therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the role of obinutuzumab (Gazyva) in the treatment of patients with follicular lymphoma.

Joseph A. Califano, MD, professor of surgery, University of California, San Diego, discusses the role of multidisciplinary care for patients with head and neck cancer.

Jeffrey M. Holzbeierlein, MD, professor, director of Urologic Oncology, Department of Urology, University of Kansas Medical Center, discusses the management guidelines for patients with bladder cancer.

Bijal D. Shah, MD, medical oncology, Moffit Cancer Center, discusses the importance of chimeric antigen receptor (CAR) T-cell therapy for patients with acute lymphoblastic leukemia (ALL).

Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the current treatment landscape of colorectal cancer.

Kanti R. Rai, MD, discusses older populations with chronic lymphocytic leukemia.

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses genetic abnormalities in multiple myeloma.

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the CABOSUN study in renal cell carcinoma (RCC).

William R. Berry, MD, medical oncologist, Duke University, discusses novel imaging techniques for patients with prostate cancer.

Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses the development of new treatment regimens for patients with early-stage lung cancer.

Peter Soyer, MD, academic dermatologist, professor, The University of Queensland Diamantina Institute, discusses the role of technology in melanoma.

Leo I. Gordon, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the role of checkpoint inhibitors for patients with hematologic malignancies.